BidaskClub upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday morning, BidAskClub reports.

Other analysts have also issued research reports about the stock. ValuEngine upgraded shares of Inovio Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, April 2nd. Roth Capital lowered shares of Inovio Pharmaceuticals from a buy rating to a neutral rating and set a $13.00 target price for the company. in a research note on Thursday, April 30th. Piper Sandler lowered shares of Inovio Pharmaceuticals from an overweight rating to a neutral rating and set a $8.00 target price for the company. in a research note on Friday, March 13th. Stifel Nicolaus lowered shares of Inovio Pharmaceuticals from a buy rating to a hold rating and boosted their target price for the company from $19.00 to $24.00 in a research note on Friday, June 26th. Finally, Royal Bank of Canada lowered shares of Inovio Pharmaceuticals to a hold rating in a research note on Monday, April 6th. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $13.56.

Shares of NASDAQ:INO opened at $26.95 on Friday. The company has a current ratio of 8.53, a quick ratio of 8.53 and a debt-to-equity ratio of 0.51. The company has a fifty day simple moving average of $15.68 and a 200 day simple moving average of $8.49. The firm has a market cap of $5.01 billion, a PE ratio of -22.65 and a beta of 1.39. Inovio Pharmaceuticals has a 12-month low of $1.91 and a 12-month high of $33.79.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.04). The company had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.55 million. Inovio Pharmaceuticals had a negative return on equity of 166.85% and a negative net margin of 4,700.42%. During the same quarter last year, the firm posted ($0.30) EPS. As a group, equities research analysts forecast that Inovio Pharmaceuticals will post -0.74 EPS for the current fiscal year.

In related news, insider Laurent Humeau sold 19,467 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $14.70, for a total value of $286,164.90. Following the completion of the sale, the insider now owns 63,433 shares of the company’s stock, valued at $932,465.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David B. Weiner sold 2,404 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $11.84, for a total transaction of $28,463.36. Following the completion of the sale, the director now directly owns 827,219 shares of the company’s stock, valued at approximately $9,794,272.96. The disclosure for this sale can be found here. Corporate insiders own 4.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of INO. Point72 Hong Kong Ltd acquired a new stake in Inovio Pharmaceuticals in the 4th quarter valued at about $37,000. Cubist Systematic Strategies LLC acquired a new stake in Inovio Pharmaceuticals in the 4th quarter valued at about $41,000. US Bancorp DE lifted its holdings in Inovio Pharmaceuticals by 568.3% in the 1st quarter. US Bancorp DE now owns 6,683 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 5,683 shares during the last quarter. Bank of Montreal Can lifted its holdings in Inovio Pharmaceuticals by 29.8% in the 4th quarter. Bank of Montreal Can now owns 17,045 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 3,912 shares during the last quarter. Finally, Ameritas Investment Partners Inc. lifted its holdings in Inovio Pharmaceuticals by 19.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 8,259 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 1,318 shares during the last quarter. 27.82% of the stock is owned by institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Recommended Story: How are dividend achievers different from dividend aristocrats?

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.